11 results about "Pulmonary vessels" patented technology

A lightweight 3D attention-based dual-path U-Net segmentation method for lung CT vessels, belonging to the field of medical image processing technology, solves the problems of low accuracy and poor segmentation of small vessels due to loss of key information when using existing techniques for vessel segmentation. The key technical points of this invention are: acquiring the image to be segmented, labeling and preprocessing the image, extracting the largest connected region of the image, constructing a DS-ResUNet network, training the DS-ResUNet network, inputting the image into the trained DS-ResUNet network, and outputting a predicted image, which is the result of dual-path U-Net segmentation of lung CT vessels. This invention is applicable to the segmentation of lung CT vessels.

The application provides application of levosulpiride in preparation of a medicine for treating pulmonary arterial hypertension, and the medicine comprises levosulpiride as an active ingredient. Through a pulmonary arterial hypertension model of a rat, the application gives an intervention treatment of levosulpiride, and the effect of levosulpiride on pulmonary vessels is determined: the levosulpiride can reduce the mean pulmonary arterial pressure of a pulmonary arterial hypertension rat, reduce pulmonary vascular resistance, and improve right ventricle and pulmonary vessel remodeling, thereby providing a strategy for developing the medicine for treating the pulmonary arterial hypertension.

This invention belongs to the field of medical image processing technology, specifically relating to a method and apparatus for quantitative analysis of microvessels in pulmonary nodules in chest CT images. The analysis method of this invention includes the following steps: Step 1, preprocessing the chest CT image; Step 2, segmenting the chest CT image using a convolutional neural network model to obtain images of the pulmonary airways, pulmonary vessels, and lung tissue; Step 3, detecting pulmonary nodules in the chest CT image using the convolutional neural network model, extracting lesions, and extracting microvessels around the lesions and within the pulmonary nodules; Step 4, calculating the microvessel density value based on the extraction results of Step 3. This invention also provides an apparatus suitable for the above analysis method. This invention can non-invasively, rapidly, and accurately display the microvessel density value in pulmonary nodules and around lesions in three dimensions, and provide precise quantitative data. It has significant clinical and socioeconomic value.

The present disclosure belongs to the technical field of biomedicine, and specifically relates to use of a malic enzyme 1 (ME1) inhibitor in preparation of a drug for preventing and treating pulmonary hypertension (PH) and as a marker for detecting and / or treating the PH. Since a protein level and / or an enzymatic activity are significantly increased in a lung tissue, the ME1 can be used as a marker for detecting or treating the PH. Meanwhile, the ME1 inhibitor can ameliorate pulmonary vascular resistance (PVR) and right ventricular involvement / right heart failure in PH patients by reducing a right ventricular systolic pressure (RVSP) and a right ventricular hypertrophy index (RVHI). Therefore, the ME1 inhibitor can be used as a therapeutic target for treating the PH, thereby increasing a medical utility of the ME1 and the ME1 inhibitor.

A method for improving an ejection fraction of a patient in need thereof, including positioning a pulmonary artery manipulation device in a target blood vessel, within the pulmonary vasculature of the patient; and impairing the activity of at least one sympathetic nerve, nerve fiber or neuron, using the pulmonary artery manipulation device, to denervate the target blood vessel, thereby improving the ejection fraction of the patient.

The invention provides a traditional Chinese medicine composition for treating pulmonary arterial hypertension and application thereof, and belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition for treating pulmonary arterial hypertension is prepared from the following components in parts by weight: 5-7 parts of herba ephedrae, 7-9 parts of semen armeniacae amarae, 20-24 parts of gypsum, 5-7 parts of liquorice root, 9-11 parts of radix salviae miltiorrhizae, 0.8-1.2 parts of leech and 2.5-3.5 parts of radix notoginseng. According to the treatment principle of freeing lung, relieving asthma and promoting blood circulation to remove blood stasis, ephedra, apricot kernel, gypsum and licorice granules with the effects of freeing lung, clearing heat and relieving asthma are used as monarch drugs, and salvia miltiorrhiza, leech and pseudo-ginseng with the effects of promoting blood circulation to remove blood stasis are used as ministerial drugs for compatibility; the prepared traditional Chinese medicine composition can reduce the length ratio of the right ventricle to the left ventricle plus ventricular septum and the length ratio of the right ventricle to the tibia, inhibit right ventricular hypertrophy, repair pulmonary vascular injury and improve the pulmonary ventilation function, the cardio-pulmonary function and pulmonary arterial hypertension.

The invention discloses a dry powder inhaler of a GLP-1 receptor stimulant and a preparation method and application of the dry powder inhaler, and belongs to the technical field of biological medicine, the dry powder inhaler comprises the following raw materials in percentage by mass: 0.01%-10% of GLP-1 drugs, 10%-99% of carriers and 0-80% of auxiliary materials, the carrier is at least two of first lactose, second lactose, mannitol, xylitol, cyclodextrin, a cyclodextrin derivative, trehalose, trehalose hydrate, dipalmitoyl lecithin, distearoyl phosphatidylcholine, glucose, amino acid and an amino acid derivative, and the prepared dry powder inhalant of the GLP-1 receptor agonist is used for pulmonary administration, has the advantages of high bioavailability and high bioavailability, and can be used for preparing the dry powder inhalant of the GLP-1 receptor agonist. The medicine can be directly inhaled into the end bronchus or alveolus of the respiratory tract in the form of particles and absorbed by the lung, and the medicine can be rapidly absorbed into blood by utilizing the characteristics of short pulmonary circulation path, thin pulmonary artery wall, multiple pulmonary vessel branches and the like, so that the medicine takes effect more rapidly.

The application discloses a lung multi-anatomy analysis and three-dimensional reconstruction method, which comprises the following steps: acquiring and preprocessing chest CT scan images to obtain input tensors; identifying and outputting airway masks and lung blood vessel masks in the input tensors by using a connected structure segmentation network; identifying and outputing lung nodule masks in the input tensors by using a micro-lesion analysis network; determining spatial physical coordinates of foreground voxels of each mask in the chest CT scan images, and determining unique anatomy class labels of each voxel by using a dynamic clinical risk priority conflict resolution strategy to obtain a multi-anatomy voxel set; and sampling and reconstructing each anatomy based on an adaptive manifold sampling strategy based on morphological characteristics to obtain reconstructed lung multi-anatomy. The method can clearly show the spatial relationship among airways, blood vessels and lesions in a unified three-dimensional coordinate system, and provides an intuitive and accurate digital model for clinical diagnosis and treatment.

The utility model belongs to the technical field of pulmonary vessel guiding catheters, and particularly relates to a pulmonary vessel guiding catheter which can be used for right heart function examination. The technology comprises a guiding catheter, and a floating catheter is arranged in the guiding catheter in a penetrating mode. According to the technical scheme, the functions of an existing right heart floating catheter and an existing pulmonary vessel guiding catheter are organically combined, and the function effects of the original right heart floating catheter and the original pulmonary vessel guiding catheter are achieved through one set of technical scheme. Specifically, a guiding catheter in the prior art is adopted, and physical characteristics such as proper flexibility and strength are utilized to adapt to various bends and steers in a blood vessel; a floating catheter in the prior art is adopted to realize pulmonary vessel intervention operation; the floating catheter is arranged in the guiding catheter, so that the guiding catheter can be used for right heart function examination and pulmonary vessel intervention operation, and clinical diversified requirements are met.

The application is suitable for the technical field of image processing, and provides a lung blood vessel segmentation method and device in a CT image, a terminal equipment and a medium. The method comprises the following steps: acquiring a lung CT image to be segmented, and inputting the lung CT image to a pre-trained lung blood vessel segmentation model to output a segmentation result of lung blood vessels in the lung CT image; the lung blood vessel segmentation model comprises an encoder and a decoder; the encoder comprises a depth separable convolution module and a Swin Transformer module, and the two modules are respectively used for acquiring local feature information and global feature information of the lung CT image to be segmented; the decoder comprises a residual module, a multi-dimensional feature calibration module, an up-sampling path and a channel splicing module; the residual module, the multi-dimensional feature calibration module, the up-sampling path and the channel splicing module are used for fusing the local feature information and the global feature information. The application can improve the segmentation accuracy of small branches of lung blood vessels.

The invention discloses a Myo9b inhibitor and application thereof in prevention and treatment of pulmonary arterial hypertension diseases, the Myo9b inhibitor is used for prevention and / or treatment of individual pulmonary arterial hypertension diseases, and the application comprises preparation of a pharmaceutical composition. The Myo9b inhibitor inhibits abnormal proliferation and migration of hypoxia-induced pulmonary artery smooth muscle cells, so that the pulmonary vascular remodeling process is slowed down, a novel Myo9b-targeted treatment strategy is provided for the pulmonary hypertension disease, and a foundation is further laid for developing a novel high-safety medicine capable of effectively treating the pulmonary hypertension disease.